AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22960817
Drug: Oral ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ivermectin 200 mcg/kg as single dose
Trial: 20960535
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with rosuvastatin (R) 5, 10, or 20 mg + fenofibric acid (FA) 135 mg
Trial: 20960535
Drug: Fenofibric acid
RxNorm normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibric acid (FA) monotherapy
Trial: 20960535
Drug: Rosuvastatin (R)
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin (R) monotherapy
Trial: 17363756
Drug: Topiramate CR
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate CR (175 mg/day)
Trial: 15712850
Drug: Coarse wheat
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coarse wheat bran (10-20 g/day)
Trial: 12577231
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy with radiation and 5-fluorouracil
Trial: 12577231
Drug: Combination therapies
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies with gemcitabine
Trial: 11334066
Drug: Erythromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (10 mg/kg IV)
Trial: 11334066
Drug: Erythromycin (additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (additional doses)
Trial: 11334066
Drug: Placebo (additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (additional doses)
Trial: 9727545
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Ticlopidine and Aspirin)
Trial: 8052456
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice cocktail (300 mL daily)
Trial: 22725648
Drug: Lidocaine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1 mg/kg bolus, followed by continuous infusion of 20 μg/kg/min after intubation)
Trial: 22725648
Drug: IV flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV flurbiprofen (1 mg/kg before skin incision)
Trial: 22725648
Drug: IV parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: IV parecoxib (40 mg before skin incision)
Trial: 11834117
Drug: Low-intensity resistance
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity resistance exercise training with 3 sets at approximately 50% 1RM and 30 seconds interset rest, performed twice a week for 12 weeks.
Trial: 10071990
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus usual medical therapy
Trial: 2553326
Drug: Intravenous nutrition
RxNorm normalized name: Intravenous nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nutrition
Trial: 30813149
Drug: Glutamine (GLN)
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine (GLN) supplementation at a dose of 10g every 8 hours (prophylactic powdered GLN orally)
Trial: 26450442
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (robot-assisted therapy plus intensive conventional therapy)
Trial: 17957152
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (2.2 g DHA and 1.1 g EPA)
Trial: 15891550
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (closed reduction and percutaneous pin fixation, open reduction and internal fixation, and arthrodesis)
Trial: 15891550
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (elevation, ice, early mobilization, cyclic compression of the plantar arch)
Trial: 24705867
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both treatments
Trial: 9987151
Drug: Vaginal mucosal
RxNorm normalized name: Mucosal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal mucosal vaccine for UTI
Trial: 18803532
Drug: 5-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day course of oral prednisolone (1 mg/kg)
Trial: 10201583
Drug: Initial medications
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial medications (n=307) with a stepped regimen to lower intraocular pressure
Trial: 10201583
Drug: Initial medications
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial medications (n=307)
Trial: 30246286
Drug: Canagliflozin 100
RxNorm normalized name: canagliflozin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 100 mg/d
Trial: 31126631
Drug: Doxycycline in
RxNorm normalized name: doxycycline Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline in combination with oral corticosteroids for 20 days
Trial: 31126631
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with oral corticosteroids for 20 days
Trial: 23726870
Drug: Repetitive transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive transcranial magnetic stimulation (rTMS) treatment for depression
Trial: 12915334
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA) supplementation, with a daily dose of up to 2.6 grams of fish oil (equivalent to about 1.6 grams of EPA)
Trial: 11910618
Drug: Prototype patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prototype patch
Trial: 11910618
Drug: Industrial counterpart
RxNorm normalized name: Counteract IB
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Industrial counterpart patch
Trial: 11910618
Drug: Reservoir patch
RxNorm normalized name: RESERVOIR,CADD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reservoir patch (Estraderm TTS 50)
Trial: 11910618
Drug: Reference matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference matrix patch (System 50)
Trial: 7835364
Drug: Elevated anticardiolipin
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated anticardiolipin antibody (ACLA) titres (IgM and IgG)
Trial: 7835364
Drug: Elevated anticardiolipin
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated anticardiolipin antibody (ACLA) titres (IgG)
Trial: 7835364
Drug: Occurrence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occurrence of anti-heart muscle antibodies (AHA) > or = 2+
Trial: 16911315
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of half-isotonic saline (1 mL/kg/h) for 12 h before surgery (hydration group)
Trial: 16911315
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of half-isotonic saline (hydration group)
Trial: 12796167
Drug: Triple drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple drug treatment (TDG) - albuterol, ipratropium bromide, and flunisolide
Trial: 12796167
Drug: A/IB (albuterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A/IB (albuterol and ipratropium bromide)
Trial: 12796167
Drug: A/F (albuterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A/F (albuterol and flunisolide)
Trial: 10968813
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg hypericum extract ZE 117 twice daily for 6 weeks
Trial: 10968813
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg imipramine twice daily for 6 weeks
Trial: 1767901
Drug: Rectal cisapride
RxNorm normalized name: Cisapride
DrugBank: Cisapride (DB00604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal cisapride 30 mg and intramuscular morphine 10 mg
Trial: 1767901
Drug: Rectal cisapride
RxNorm normalized name: Cisapride
DrugBank: Cisapride (DB00604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal cisapride 60 mg and intramuscular morphine 10 mg
Trial: 1767901
Drug: Placebo suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suppositories and intramuscular morphine 10 mg
Trial: 1767901
Drug: Placebo suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suppositories only
Trial: 29066145
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen (4 doses of 1 g over 15 minutes every 6 hours for 24 hours)
Trial: 29066145
Drug: IV placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV placebo (saline placebo, equal volume to acetaminophen)
Trial: 26875489
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg menaquinone-7 daily for 12 weeks (Study 2)
Trial: 26875489
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg menaquinone-7 daily for 4 weeks (Study 1)
Trial: 26875489
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg menaquinone-7 daily for 4 weeks (Study 1)
Trial: 26875489
Drug: 0 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 μg menaquinone-7 daily (Study 1)
Trial: 19519874
Drug: Diode laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode laser (DL) and placebo gel
Trial: 19519874
Drug: Placebo laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo laser and NK10% gel
Trial: 19519874
Drug: Placebo laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo laser and placebo gel
Trial: 17198098
Drug: Epinephrine-containing lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine-containing lidocaine solution (40 microg, 2.5 microg/mL)
Trial: 17198098
Drug: Epinephrine-containing lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine-containing lidocaine solution (80 microg, 5 microg/mL)
Trial: 17198098
Drug: Epinephrine-containing lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine-containing lidocaine solution (160 microg, 10 microg/mL)
Trial: 17198098
Drug: Epinephrine-containing lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine-containing lidocaine solution (all groups)
Trial: 15072808
Drug: Fluvoxamine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (up to 300 mg per day) plus counselling and support
Trial: 7663138
Drug: Nadolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (80 mg p.o.)
Trial: 7663138
Drug: Isosorbide‐5‐mononitrate (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide‐5‐mononitrate (20 mg p.o.)
Trial: 2660562
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g twice per day)
Trial: 2660562
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg before bed)
Trial: 22745189
Drug: Sulpiride (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (400 mg, selective D2 antagonist)
Trial: 16822120
Drug: Homework compliance
RxNorm normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Homework compliance during cognitive-behavioral therapy (CBT)
Trial: 8472110
Drug: Carbon dioxide
RxNorm normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbon dioxide (CO2) as the insufflation agent
Trial: 8472110
Drug: Air as
RxNorm normalized name: OCTINOXATE 2010 mg in 30 mL / OCTOCRYLENE 900 mg in 30 mL / TITANIUM DIOXIDE 600 mg in 30 mL TOPICAL EMULSION [SHISEIDO SYNCHRO SKIN SELF-REFRESHING TINT 125 Fair Asterid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air as the insufflation agent
Trial: 23845716
Drug: Low-dose computed
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose computed tomography screening
Trial: 27191255
Drug: Maxillary canine
RxNorm normalized name: CanineAid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxillary canine retraction using mini-implants as anchorage for approximately 4 months with 100g of force via coil springs.
Trial: 27191255
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no orthodontic treatment).
Trial: 19922572
Drug: Intramuscular naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular naloxone (2 mg)
Trial: 10570736
Drug: Mechanical support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical support of minute ventilation for chronic but stable diseases (e.g., old polio, quadriplegia, kyphoscoliosis)
Trial: 10570736
Drug: Mechanical support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical support of minute ventilation for chronic and progressive diseases (e.g., muscular dystrophy, amyotrophic lateral sclerosis)
Trial: 7598463
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment of IDDM patients
Trial: 7598463
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment recommendations
Trial: 7598463
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of insulin in NIDDM patients
Trial: 786832
Drug: Control (antiphologistic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (antiphologistic containing high dosage of vitamin B complex and Metamizol)
Trial: 27387522
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy (non-ASV)
Trial: 25289711
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g L-carnitine
Trial: 25289711
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g L-carnitine
Trial: 22164964
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium enteric coated tablets (test formulation)
Trial: 22164964
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium enteric coated tablets (reference formulation)
Trial: 11096234
Drug: Intermittent hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent hormonal deprivation using luteinizing hormone-releasing hormone (LHRH) analogue alone (n = 11)
Trial: 8354733
Drug: Fluvoxamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (50 or 100 mg)
Trial: 8354733
Drug: Fluvoxamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (50 or 100 mg) + Ethanol (0.8 g/kg)
Trial: 3564877
Drug: Bain system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bain system at VF of 125 ml X min‐1 X kg‐1 b.w.
Trial: 3564877
Drug: Bain system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bain system at VF of 100 ml X min‐1 X kg‐1 b.w.
Trial: 3564877
Drug: Lack system
RxNorm normalized name: allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lack system at VF of 70 ml X min‐1 X kg‐1 b.w.
Trial: 3564877
Drug: Lack system
RxNorm normalized name: allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lack system at VF of 55 ml X min‐1 X kg‐1 b.w.
Trial: 30513923
Drug: CPO (composite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPO (composite supplement containing collagen peptide and ornithine)
Trial: 20202953
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of oral indomethacin
Trial: 10703539
Drug: GADA (glutamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GADA (glutamic acid decarboxylase antibodies)
Trial: 10703539
Drug: ICA (islet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICA (islet cell antibodies)
Trial: 8697549
Drug: Rocuronium continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium continuous infusion starting at 0.6 mg.kg‐1.hr‐1, adjusted by 0.1 mg.kg‐1.hr‐1 to maintain one visible twitch of the TOF.
Trial: 1757603
Drug: Halobetasol propionate
RxNorm normalized name: Halobetasol Propionate
DrugBank: Ulobetasol (DB00596)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halobetasol propionate ointment
Trial: 23528398
Drug: 1% emoxipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% emoxipine solution
Trial: 23528398
Drug: 1.5% reamberin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% reamberin solution
Trial: 23528398
Drug: 5% mexidol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% mexidol solution
Trial: 21647846
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of EMLA (2.5% lidocaine and 2.5% prilocaine)
Trial: 18796000
Drug: Pamidronate 90
RxNorm normalized name: pamidronate 90 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 90 mg/IV within the first 2 weeks and at 3 months after transplantation
Trial: 18796000
Drug: Placebo (glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (glucose infusions at the same time points)
Trial: 18796000
Drug: Pamidronate 90
RxNorm normalized name: pamidronate 90 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 90 mg/IV
Trial: 16774715
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (Control in IS study)
Trial: 14992899
Drug: Hypothermic protective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermic protective solution
Trial: 11698275
Drug: 7.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg/kg rabbit ATG (Thymoglobulin)
Trial: 11698275
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg rabbit ATG
Trial: 9293721
Drug: PRP-T Hib
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP-T Hib conjugate vaccine
Trial: 8282480
Drug: Human recombinant
RxNorm normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human recombinant interferon-alpha (rIFN-alpha) at a dose of 3 x 10(6) units thrice weekly for three months, followed by 1.5 x 10(6) units thrice weekly for the next three months
Trial: 27843803
Drug: Duligotuzumab (1100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duligotuzumab (1100 mg IV, q2w)
Trial: 27843803
Drug: Cetuximab (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (400 mg/m2 load, 250 mg/m2 IV, q1w)
Trial: 25665116
Drug: FLOSEAL 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLOSEAL 5 mL
Trial: 25665116
Drug: FLOSEAL 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLOSEAL 10 mL
Trial: 23046438
Drug: Black currant
RxNorm normalized name: Black currant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black currant anthocyanins (BCACs) 50 mg/day
Trial: 21966075
Drug: DXP 3
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DXP 3 mg
Trial: 21966075
Drug: DXP 6
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DXP 6 mg
Trial: 16702703
Drug: Clinical actions
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical actions (e.g., speak positively about treatments, provide encouragement)
Trial: 12811019
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with standardized ragweed pollen extract tablets
Trial: 12811019
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with highest dose (3 tablets 3 times a week)
Trial: 8649658
Drug: 1.25 mmol/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mmol/l Ca dialysate
Trial: 8649658
Drug: 1.75 mmol/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.75 mmol/l Ca dialysate